MEMPHASYS LIMITED. — Capital/Financing Update 2026

Feb 5, 2026

6 February 2026

==> picture [195 x 46] intentionally omitted <==

ASX Release ASX Code: MEM

Memphasys’ $800,000 Capital Raise Strongly Supported as Investors Back Felix Commercial Growth

Highlights

• Firm commitments received to raise $0.8M through a share placement at an issue price of $0.005, representing a 28.6% discount to the last closing price

• The Placement was strongly supported by new and existing sophisticated and professional investors

• • Proceeds from the Placement will be used to support Felix™ commercial execution, including expansion of the direct selling model, manufacturing cartridges to meet growing customer demand, regulatory progression and working capital as the Company advances recent commercial and regulatory milestones.

Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) is pleased to announce that it has secured firm commitments from sophisticated and professional investors to raise $0.8M (before costs) at an issue price of $0.005 per share (the “Placement”). The Placement was strongly supported by both new and existing institutional investors, sophisticated and professional investors.

The Placement follows a period of accelerating regulatory and commercial momentum for the Company, including CE Mark approval for the Felix™ System, the commencement of invoiced revenues across multiple international markets, and the lodgement of key regulatory submissions in Australia and India.

Proceeds from the Placement will be applied towards advancing Felix™ commercialisation execution, including scaling direct selling and clinical engagement activities, supporting manufacturing readinesss and inventory build to meet growing contracted and anticipated demand, and progressing regulatory approvals in key markets.

Placement Details

The Placement comprises the issue of a total of 160,000,000 fully paid ordinary shares at an issue price of $0.005 per share, raising $0.8M (before costs) to institutional, sophisticated and professional investors. The 160,000,000 placement shares will be issued under the Memphasys’ existing ASX Listing Rule 7.1 placement capacity.

The issue price of the placement represents a 28.6% discount to the last trading price of $0.007 on 3 February 2026 and a 22.5% discount to the 10-day volume weighted average price (“VWAP”) of $0.0064.

The new shares will rank equally with existing Memphasys fully paid ordinary shares quoted on the ASX.

Settlement of the placement is expected to occur on Friday, 13 February 2026, with the Shares to be allotted on or around Monday, 16 February 2026.

Lynx Advisors Pty Ltd acted as Lead Manager to the Placement.

Memphasys Limited Level 1, 34-36 Richmond Road Homebush West, NSW 2140

E info@memphasys.com W memphasys.com ABN 33 120 047 556

Contact Details P +612 8415 7300

– 2 –

“I am very pleased to see the strong support for this capital raise from both new and existing shareholders,” said Dr Lindley Edwards, Chair of Memphasys.

“With CE Mark approval secured, initial revenues now being invoiced, contracted demand in place and regulatory submissions lodged in key markets, this funding allows Memphasys to accelerate commercial execution of Felix™ and build momentum as the Company transitions into a recurring revenue phase.”

Authorised by the Board of Memphasys Limited.

Ends

For further information, please contact:

David Tasker Managing Director Chapter One Advisors Tel: +61 433 112 936 E: dtasker@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.

By combining electrophoresis and size-exclusion membranes, Felix™ delivers a fast, gentle and standardised sperm selection process that enhances sperm quality and reduces laboratory time. The system replaces traditional centrifugation, which can cause cellular stress and DNA damage, offering clinicians a superior, repeatable alternative.

Memphasys’ commercial strategy focuses on building contracted sales through direct and distribution-led channels, scaling production to improve margins, and establishing Felix™ as a new global standard in sperm preparation for ART procedures.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.